Physician profile
Daniela L Bignoli
NPI 1427631555
$828.23
in general payments reported to CMS, 2019-2025
10 companies · $573 in 2025
The $573 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $17.28 · 2024: $238 · 2025: $573.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $828.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $828.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $219.16 | 2024-2025 | |
| Novo Nordisk INC | $156.43 | 2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $137.58 | 2025 | Zepbound, Mounjaro |
| Pfizer INC. | $132.03 | 2023-2025 | |
| Exact Sciences Corporation | $59.55 | 2024-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $41.01 | 2025 | Arexvy |
| Abbott Laboratories | $23.07 | 2025 | Freestyle Libre |
| Janssen Pharmaceuticals, INC | $20.83 | 2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $19.63 | 2025 | Farxiga |
| Novartis Pharmaceuticals Corporation | $18.94 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniela Bignoli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.